These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 2908815)

  • 1. Human vasodilator responses to a dopamine agonist: possible mechanisms.
    Redman D; Thom SA; Hughes AD; Hasan S; Sever PS
    J Hypertens Suppl; 1985 Dec; 3(3):S177-8. PubMed ID: 2908815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonism of a specific dopaminergic receptor agonist with metoclopramide in horses.
    Eades SC; Moore JN
    Am J Vet Res; 1993 Jan; 54(1):122-5. PubMed ID: 8093992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of dopamine DA1-receptor blockade and angiotensin converting enzyme inhibition on the renal actions of fenoldopam in the anaesthetized dog.
    Clark KL; Hilditch A; Robertson MJ; Drew GM
    J Hypertens; 1991 Dec; 9(12):1143-50. PubMed ID: 1685741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SK&F 87516, a close analog of fenoldopam, is a partial agonist at dopamine-1 and alpha-2 receptors and produces stimulation of 5-hydroxytryptamine-2 receptors in the cardiovascular system of the rat.
    Le Monnier de Gouville AC; Lawson K; Thiry C; Cavero I
    J Pharmacol Exp Ther; 1991 Mar; 256(3):1049-56. PubMed ID: 1672375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of fenoldopam on cecal blood flow and mechanical activity in horses.
    Clark ES; Moore JN
    Am J Vet Res; 1989 Nov; 50(11):1926-30. PubMed ID: 2575878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective dopamine DA1 stimulation with fenoldopam in cirrhotic patients with ascites: a systemic, splanchnic and renal hemodynamic study.
    Hadengue A; Moreau R; Bacq Y; Gaudin C; Braillon A; Lebrec D
    Hepatology; 1991 Jan; 13(1):111-6. PubMed ID: 1671029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the effects of dopamine-1 and dopamine-2 receptor agonists on coronary flow.
    Zhao RR; Wang PH; Zhang WF; Fennell WH
    Methods Find Exp Clin Pharmacol; 1992; 14(1):5-11. PubMed ID: 1352371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence from functional and autoradiographic studies for the presence of tubular dopamine-1 receptors and their involvement in the renal effects of fenoldopam.
    Hedge SS; Ricci A; Amenta F; Lokhandwala MF
    J Pharmacol Exp Ther; 1989 Dec; 251(3):1237-45. PubMed ID: 2574743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular responses in healthy subjects to a novel oral dopamine agonist, fenoldopam.
    Cregeen RJ; Rudge PJ; Mills JG; Vincent SH; Burland WL
    J Hypertens Suppl; 1985 Dec; 3(3):S173-5. PubMed ID: 2908814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fenoldopam is a partial agonist at dopamine-1 (DA1) receptors in LLC-PK1 cells.
    Grenader A; Healy DP
    J Pharmacol Exp Ther; 1991 Jul; 258(1):193-8. PubMed ID: 1677038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular and renal hemodynamic effects of A-68930 in the conscious dog: a comparison with fenoldopam.
    Christie MI; Smith GW
    J Pharmacol Exp Ther; 1994 Feb; 268(2):565-70. PubMed ID: 7906731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrarenally produced angiotensin II opposes the natriuretic action of the dopamine-1 receptor agonist fenoldopam in rats.
    Chen CJ; Apparsundaram S; Lokhandwala MF
    J Pharmacol Exp Ther; 1991 Feb; 256(2):486-91. PubMed ID: 1671595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional ontogeny of pulmonary vascular DA1 dopamine receptors in the isolated perfused rabbit lung.
    Polak MJ; Taylor DA
    Pediatr Res; 1994 Feb; 35(2):228-32. PubMed ID: 7909367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of dopamine and fenoldopam effects on renal blood flow and prostacyclin excretion in normal and essential hypertensive subjects.
    Bughi S; Horton R; Antonipillai I; Manoogian C; Ehrlich L; Nadler J
    J Clin Endocrinol Metab; 1989 Dec; 69(6):1116-21. PubMed ID: 2573613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the hemodynamic activities of fenoldopam and its enantiomers in the dog.
    Kinter LB; Horner E; Mann WA; Weinstock J; Ruffolo RR
    Chirality; 1990; 2(4):219-25. PubMed ID: 1982058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacology of fenoldopam.
    Nichols AJ; Ruffolo RR; Brooks DP
    Am J Hypertens; 1990 Jun; 3(6 Pt 2):116S-119S. PubMed ID: 1974439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of fenoldopam on the acute and subacute nephrotoxicity produced by amphotericin B in the dog.
    Nichols AJ; Koster PF; Brooks DP; Ruffolo RR
    J Pharmacol Exp Ther; 1992 Jan; 260(1):269-74. PubMed ID: 1346161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcitonin gene-related peptide-induced vasodilation in the human forearm is antagonized by CGRP8-37: evaluation of a human in vivo pharmacodynamic model.
    Vanmolkot FH; Van der Schueren BJ; de Hoon JN
    Clin Pharmacol Ther; 2006 Mar; 79(3):263-73. PubMed ID: 16513450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-Hydroxytryptamine receptor activity of the dopamine receptor agonist fenoldopam in canine tracheal smooth muscle.
    Gretler DD; Jones KC; Murphy MB
    J Pharmacol Exp Ther; 1992 Feb; 260(2):491-8. PubMed ID: 1346635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the effects of dopamine and fenoldopam, a selective dopamine-1 agonist, on parathyroid hormone release in man.
    Bakris GL; Weber RR; Nelson K; Elliott WJ; Kaplan E; Murphy MB
    Miner Electrolyte Metab; 1988; 14(6):343-6. PubMed ID: 2906737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.